Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. - Test2 - elhamkhani - TriplyDB

Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.

Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.

http://www.wikidata.org/entity/Q37832198

about

The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications Time trends of cancer mortality among elderly in Italy, 1970-2008: an observational study.Antibody therapy of pediatric B-cell lymphoma Characterization of HIV-associated Hodgkin's lymphoma in HIV-infected patients: a single-center experience.Hodgkin lymphoma in patients with HIV infection: a review.EBV primary infection in childhood and its relation to B-cell lymphoma development: a mini-review from a developing region.Diagnosis and management of lymphomas and other cancers in HIV-infected patients.Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years.Epstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cells.Skin involvement with Hodgkin disease: a rare condition late in the course of Hodgkin lymphoma.Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder, Hodgkin type, following Epstein-Barr Viral Hepatitis in a Patient with Rheumatoid Arthritis.

P2860

Q26991549-E5B21F5E-07BD-4E39-AC63-71DF50AD2EC2 Q27011510-DFA3A421-AF49-4D38-9035-87E728C5B62D Q34432508-564320F2-64BF-4B03-B166-F958D365F067 Q36732959-B3FF1BF7-8861-41AB-A0F9-1D4F418FB75B Q37981081-097CD15B-01C1-4CCF-8522-9E7F6E52DD7C Q38006636-2F6053A6-63A0-4979-BE5C-71ED77E82CB1 Q38045798-928A408B-2AA5-4481-9449-E0CF9AB2C520 Q38194845-0815AF40-4CC1-4F51-892E-D3885C3091D7 Q39279200-E4FA6A86-CCD1-46D5-8882-D75630907D83 Q42272470-AEFA89BF-6297-4B4A-AAC7-E5D7AA424A8D Q45843445-72F7E685-2019-4640-B009-0D1CD712254D Q47560339-FB813E5F-A2B2-43EB-8E9A-43E004C0FAE2

P2860

Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.

http://www.wikidata.org/entity/Q37832198

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@en

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@nl

type

label

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@en

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@nl

prefLabel

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@en

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@nl

P1433

Q37832198-41330526-24CC-4907-BCA2-3E79E2123A71

P1476

Q37832198-DB67C28F-8FC8-421D-B6CB-D4DE5A0518C0

P2093

Q37832198-0BE01C59-68A7-41D9-9857-F0CD5EB7FE06

Q37832198-53583C96-3125-485C-9F4D-38762E9AC286

Q37832198-CDB63508-94B6-415E-A4E6-B8F52727BC95

Q37832198-E494FE8F-853A-4633-ADC6-EDADF4DB15FD

P2860

Q37832198-0211003E-4102-4777-AE23-6245178D6CFA

Q37832198-05178711-E0B0-4F0C-994A-727D2C4A74B0

Q37832198-0797F36C-5CE3-45E1-A1CA-37638C1B6A5F

Q37832198-081D8C7E-4208-4985-AB31-DDE44489FC3F

Q37832198-089F73F0-A854-4953-AB95-6D154155A8BB

Q37832198-09671FDB-9D54-45AB-BDBA-3D163E2826FE

Q37832198-0BA53F23-7D1A-4B97-888E-5B74F4ACBE61

Q37832198-0C32D5A2-3DF1-497A-B52D-5554012F2564

Q37832198-10692B32-7BAD-4AE2-A55C-EDFCD8134F9F

Q37832198-1174AA35-6B8B-4435-BD3F-293739D49B12

P304

Q37832198-B99EB3F9-D085-4B03-A9DC-5F3FA8D4AC7B

P31

Q37832198-F1B5B035-0220-44F7-B320-87A12F85F591

P356

Q37832198-A1030136-8471-4AAF-A6AD-A1FC90214DC8

P433

Q37832198-32BCD048-7190-4787-9416-C3252908DFED

P478

Q37832198-A9DA32B4-E061-424F-A0D0-87E3ABD770FB

P577

Q37832198-28C0C8FD-DA4F-43AB-B20E-88387F0FE34B

P5875

Q37832198-3090443B-889A-4565-8710-2974A43141BC

P698

Q37832198-E67EB69E-D638-4CE3-B1EA-3936D2050F44

P356

P1433

American Journal of Hematology

P1476

Classical Hodgkin's lymphoma a ...... rapeutic options, and outcome.

@en

P2093

Annunziata Gloghini

http://www.w3.org/2001/XMLSchema#string

Antonino Carbone

http://www.w3.org/2001/XMLSchema#string

Michele Spina

http://www.w3.org/2001/XMLSchema#string

Umberto Tirelli

http://www.w3.org/2001/XMLSchema#string

P2860

Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

P304

170-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.21910

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49783534

http://www.w3.org/2001/XMLSchema#string

P698

21264899

http://www.w3.org/2001/XMLSchema#string